Opendata, web and dolomites

OncoMasTR

OncoMasTR - Novel Prognostic Assay for Early Stage Breast Cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "OncoMasTR" data sheet

The following table provides information about the project.

Coordinator
ONCOMARK LIMITED 

Organization address
address: 172 RATHGAR ROAD RATHGAR
city: DUBLIN
postcode: Dublin 6
website: www.oncomark.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website http://www.oncomastr.com
 Total cost 2˙751˙250 €
 EC max contribution 2˙751˙250 € (100%)
 Programme 1. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
2. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-2-2015
 Funding Scheme SME-2
 Starting year 2016
 Duration (year-month-day) from 2016-02-01   to  2018-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    ONCOMARK LIMITED IE (DUBLIN) coordinator 2˙751˙250.00

Map

 Project objective

OncoMark Ltd are developing a novel, game-changing breast cancer prognostic assay, called OncoMasTR, which has the potential to transform clinical practice and patient care. OncoMasTR will help clinicians to decide which patients should receive chemotherapy for early stage breast cancer, which is a pressing clinical and economic issue worldwide. OncoMasTR is more cost-effective than competitor assays, demonstrates superior performance clinically, generates a user-friendly binary (yes/no) output and can be carried out on-site using standard equipment. Our principal aim is to develop OncoMasTR as a CE marked kit, and penetrate a global market.

OncoMasTR comprises a novel panel of biomarkers of tumour progression, measured by qRT-PCR using standard procedures and equipment. Objectives for Phase 2 are to analytically, clinically and commercially validate the OncoMasTR prototype under ISO13485 standards, using two large cohorts of breast cancer patients. Access to tissues from a prospective clinical trial will enable us to benchmark OncoMasTR’s performance against the leading competitor assay. Communication and dissemination of data will be key to building a strong base of OncoMasTR ambassadors in the clinical arena, and to leverage private investment in OncoMark for development of other products in our pipeline. OncoMasTR will bring OncoMark into the clinical biomarker arena and will positively impact healthcare costs in the EU and globally.

 Deliverables

List of deliverables.
Launch of project webpage Websites, patent fillings, videos etc. 2019-05-30 15:02:58

Take a look to the deliverables list in detail:  detailed list of OncoMasTR deliverables.

 Publications

year authors and title journal last update
List of publications.
2017 Barron S, Jirström K, Jernström H, Ingvar C, Moran B, Wang C-JA, Loughman T, Fender B, Dynoodt P, Lopez-Ruiz C, Russell N, Gallagher WM
Prognostic value of OncoMasTR: A novel multigene signature based on master transcriptional regulators
published pages: , ISSN: , DOI:
SABCS Abstract Book 2019-06-13

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ONCOMASTR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ONCOMASTR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.3.;H2020-EU.3.1.3.)

PReDicT (2015)

Predicting Response to Depression Treatment

Read More  

FETAL MONITORING (2016)

Safe and accurate fetal monitoring

Read More  

MPIPETrace (2015)

Clinical performance validation of a novel biomarker for quantitative imaging of coronary artery disease.

Read More